FSD Pharma (CSE:HUGE, NASDAQ:HUGE) Inc has announced the appointments of David Allan and John McGraw to its advisory board.
Allan is principal at Cresswell Advisors Inc and has worked in several leading biotechnology companies that were acquired by names like Bristol Myers Squibb and Pfizer. He also currently serves as managing director and board member of eQcell Inc, a One Health company, the first to be cleared by Health Canada for clinical trials in equine osteoarthritis with mesenchymal stromal cells.
McGraw, a PhD, has more than 20 years of executive experience commercializing health technologies including medical devices, therapeutics, and health services. He is currently president and director at Izotropic Corporation, a company developing a dedicated breast computed tomography imaging platform, and president of Spratley Advisors, an advisory company with drug development experience across many therapeutic areas.
READ: FSD Pharma announces expansion of its management and advisory teams
"Mr Allan and Dr McGraw both have impressive careers in the field of healthcare and biotechnology underscored by tremendously successful exits and we are excited to welcome them to our team," FSD interim CEO Anthony Durkacz told investors.
"Our drug candidates have attracted an unparalleled group of advisors and staff as we position to initiate clinical trials, and the talents of these two seasoned industry executives joining in our mission to improve patient outcomes in challenging diseases such as multiple sclerosis, major depression disorder and inflammatory disorders," he added.
FSD Pharma (CSE:HUGE, NASDAQ:HUGE) is a Toronto-based biotechnology company with three drug candidates in different stages of development.
Contact Angela at angela@proactiveinvestors.com
Follow her on Twitter @AHarmantas